199 related articles for article (PubMed ID: 33347392)
1. Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations.
Hu M; Zhang T; Gu M; Li J; Zhang H; Wang Q; Hu F; Yang Y; Li B
Genet Test Mol Biomarkers; 2020 Dec; 24(12):798-803. PubMed ID: 33347392
[No Abstract] [Full Text] [Related]
2. Clinical implications of serum hypoxia inducible factor-1α and vascular endothelial growth factor in lung cancer.
Shen H; Feng G; Cui J; Du Q; Qin Y; Cai J; Shen L; Zhu Y
Tumori; 2015; 101(4):404-11. PubMed ID: 25983091
[TBL] [Abstract][Full Text] [Related]
3. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
4. Serum tumor markers, hypoxia-inducible factor-1α HIF-1α and vascular endothelial growth factor, in patients with non- small cell lung cancer before and after intervention.
Liang J; Qian Y; Xu D; Yin Q; Pan HJ
Asian Pac J Cancer Prev; 2013; 14(6):3851-4. PubMed ID: 23886195
[TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma binding protein 2 (RBP2) promotes HIF-1α-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.
Qi L; Zhu F; Li SH; Si LB; Hu LK; Tian H
PLoS One; 2014; 9(8):e106032. PubMed ID: 25162518
[TBL] [Abstract][Full Text] [Related]
6. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of the expression of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha in patients undergoing surgery for non-small cell lung cancer].
Honguero Martínez AF; Arnau Obrer A; Figueroa Almazán S; Martínez Hernández N; Guijarro Jorge R
Med Clin (Barc); 2014 May; 142(10):432-7. PubMed ID: 23948151
[TBL] [Abstract][Full Text] [Related]
9. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Yasuda H; Nakayama K; Watanabe M; Suzuki S; Fuji H; Okinaga S; Kanda A; Zayasu K; Sasaki T; Asada M; Suzuki T; Yoshida M; Yamanda S; Inoue D; Kaneta T; Kondo T; Takai Y; Sasaki H; Yanagihara K; Yamaya M
Clin Cancer Res; 2006 Nov; 12(22):6748-57. PubMed ID: 17121895
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α Levels in patients receiving chemoradiotherapy for locally advanced non-small cell lung carcinoma.
Afsar CU; Uysal P
Rev Assoc Med Bras (1992); 2019; 65(10):1295-1299. PubMed ID: 31721962
[TBL] [Abstract][Full Text] [Related]
11. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
Dudek AZ; Mahaseth H
Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
13. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
14. Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.
Strimpakos AS; Banerji U; Thavasu P; Tsilimagou A; Psyrri A; Syrigos KN
Oncology; 2015; 89(1):53-9. PubMed ID: 25766505
[TBL] [Abstract][Full Text] [Related]
15. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
16. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.
Chang CC; Lin MT; Lin BR; Jeng YM; Chen ST; Chu CY; Chen RJ; Chang KJ; Yang PC; Kuo ML
J Natl Cancer Inst; 2006 Jul; 98(14):984-95. PubMed ID: 16849681
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
18. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
19. Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Berk V; Deniz K; Bozkurt O; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(14):6149-54. PubMed ID: 26320510
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and prognostic significance of hypoxia-inducible factor-1 alpha in lung cancer: a systematic review with meta-analysis.
Yang SL; Ren QG; Wen L; Hu JL
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):321-327. PubMed ID: 27376798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
